- Home
- ACRS vs VOXR Comparison
ACRS vs VOXR Comparison
Compare ACRS & VOXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- VOXR
- Stock Information
- Founded
- ACRS 2012
- VOXR 2014
- Country
- ACRS United States
- VOXR Canada
- Employees
- ACRS N/A
- VOXR N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- VOXR Precious Metals
- Sector
- ACRS Health Care
- VOXR Basic Materials
- Exchange
- ACRS Nasdaq
- VOXR Nasdaq
- Market Cap
- ACRS 132.0M
- VOXR 125.5M
- IPO Year
- ACRS 2015
- VOXR N/A
- Fundamental
- Price
- ACRS $2.60
- VOXR $2.43
- Analyst Decision
- ACRS Strong Buy
- VOXR
- Analyst Count
- ACRS 5
- VOXR 0
- Target Price
- ACRS $11.00
- VOXR N/A
- AVG Volume (30 Days)
- ACRS 956.3K
- VOXR 100.6K
- Earning Date
- ACRS 02-25-2025
- VOXR 03-06-2025
- Dividend Yield
- ACRS N/A
- VOXR 1.98%
- EPS Growth
- ACRS N/A
- VOXR N/A
- EPS
- ACRS N/A
- VOXR N/A
- Revenue
- ACRS $27,079,000.00
- VOXR $11,147,864.00
- Revenue This Year
- ACRS N/A
- VOXR N/A
- Revenue Next Year
- ACRS N/A
- VOXR $2.02
- P/E Ratio
- ACRS N/A
- VOXR N/A
- Revenue Growth
- ACRS 26.35
- VOXR N/A
- 52 Week Low
- ACRS $0.95
- VOXR $1.70
- 52 Week High
- ACRS $5.17
- VOXR $3.24
- Technical
- Relative Strength Index (RSI)
- ACRS 44.33
- VOXR 51.16
- Support Level
- ACRS $2.31
- VOXR $2.29
- Resistance Level
- ACRS $2.64
- VOXR $2.44
- Average True Range (ATR)
- ACRS 0.16
- VOXR 0.07
- MACD
- ACRS 0.02
- VOXR 0.02
- Stochastic Oscillator
- ACRS 58.76
- VOXR 80.95
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of over 60 royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector.